OTC Medicines

(WASHINGTON, D.C.) The Consumer Healthcare Products Association (CHPA) today announced the election of new members to its board of directors during the association’s summer meeting this week in Washington.

CHPA released the below statement today following Governor Phil Scott signing S. 187 into law this week, legislation that will allow students to carry and self-apply sunscreen at school with the permission of a parent or guardian.

CHPA released the below statement today following Tennessee Governor Bill Lee's recent signing of Senate Bill 2048 into law, legislation that raises the monthly purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE) from 5.76 grams per month to 7.2 grams, allowing access to a full 30-day supply per month. The bill also raises the annual purchase limit to 43.2 grams, which is a 40% increase from the current limit of 28.8 grams.

CHPA Response to Study Published in Neurology Clinical Practice, Examining Prescription Acid Reflux Drugs:

In recent years, the issue of consumer data privacy has become increasingly important as technology continues to advance, and more personal information is collected and shared online. Despite the growing concerns over data privacy, the federal government has yet to enact comprehensive legislation addressing the issue. This lack of federal action has prompted many states to take matters into their own hands and introduce their own data privacy laws to protect their residents.

(WASHINGTON, D.C.) – Representatives from the Consumer Healthcare Products Association (CHPA), Sanofi Consumer Healthcare, Haleon, Kenvue, and Bayer participated in a discussion this week hosted by U.S. Rep. Bob Latta (OH-05) to provide an analysis of the over-the-counter (OTC) Monograph Drug User Fee Program (OMUFA), how some OTCs come to market through the Rx-to-OTC-switch process, how these products are regulated by the U.S. Food and Drug Administration (FDA), and industry’s efforts to expand HSA/FSA coverage for dietary supplements and oral care products.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.

“Consumers can be confident that over-the-counter (OTC) acne products containing benzoyl peroxide (BPO) are stable and safe under the specified storage conditions on their labels.